Drugs for Central Nervous System Diseases Market, Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: D7260A9C779FEN
Market Monitor Global

Abstracts

A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system

This report contains market size and forecasts of Drugs for Central Nervous System Diseases in Global, including the following market information:

Global Drugs for Central Nervous System Diseases Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Drugs for Central Nervous System Diseases market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Antidepressants Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Drugs for Central Nervous System Diseases include Alkermes, Astrazeneca, Biogen, Bristol Myers Squibb, Lilly, GSK, Merck, Sunovion?Pharmaceuticals and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Central Nervous System Diseases companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Drugs for Central Nervous System Diseases Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Drugs for Central Nervous System Diseases Market Segment Percentages, by Type, 2021 (%)

• Antidepressants
• Anxiolytics
• Anti-manic
• Other

Global Drugs for Central Nervous System Diseases Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Drugs for Central Nervous System Diseases Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Drugs for Central Nervous System Diseases Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Drugs for Central Nervous System Diseases Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Drugs for Central Nervous System Diseases revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Drugs for Central Nervous System Diseases revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Alkermes
• Astrazeneca
• Biogen
• Bristol Myers Squibb
• Lilly
• GSK
• Merck
• Sunovion?Pharmaceuticals
• Pfizer
• Teva
• Norvatis

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Drugs for Central Nervous System Diseases Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Drugs for Central Nervous System Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES OVERALL MARKET SIZE

2.1 Global Drugs for Central Nervous System Diseases Market Size: 2021 VS 2028
2.2 Global Drugs for Central Nervous System Diseases Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Drugs for Central Nervous System Diseases Players in Global Market
3.2 Top Global Drugs for Central Nervous System Diseases Companies Ranked by Revenue
3.3 Global Drugs for Central Nervous System Diseases Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Central Nervous System Diseases Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drugs for Central Nervous System Diseases Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Players in Global Market
  3.6.1 List of Global Tier 1 Drugs for Central Nervous System Diseases Companies
  3.6.2 List of Global Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Drugs for Central Nervous System Diseases Market Size Markets, 2021 & 2028
  4.1.2 Antidepressants
  4.1.3 Anxiolytics
  4.1.4 Anti-manic
  4.1.5 Other
4.2 By Type - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
  4.2.1 By Type - Global Drugs for Central Nervous System Diseases Revenue, 2017-2022
  4.2.2 By Type - Global Drugs for Central Nervous System Diseases Revenue, 2023-2028
  4.2.3 By Type - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Drugs for Central Nervous System Diseases Market Size, 2021 & 2028
  5.1.2 Hospital Pharmacies
  5.1.3 Retail Pharmacies
  5.1.4 Online Pharmacies
5.2 By Application - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
  5.2.1 By Application - Global Drugs for Central Nervous System Diseases Revenue, 2017-2022
  5.2.2 By Application - Global Drugs for Central Nervous System Diseases Revenue, 2023-2028
  5.2.3 By Application - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Drugs for Central Nervous System Diseases Market Size, 2021 & 2028
6.2 By Region - Global Drugs for Central Nervous System Diseases Revenue & Forecasts
  6.2.1 By Region - Global Drugs for Central Nervous System Diseases Revenue, 2017-2022
  6.2.2 By Region - Global Drugs for Central Nervous System Diseases Revenue, 2023-2028
  6.2.3 By Region - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Drugs for Central Nervous System Diseases Revenue, 2017-2028
  6.3.2 US Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.3.3 Canada Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.3.4 Mexico Drugs for Central Nervous System Diseases Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Drugs for Central Nervous System Diseases Revenue, 2017-2028
  6.4.2 Germany Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.3 France Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.4 U.K. Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.5 Italy Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.6 Russia Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.7 Nordic Countries Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.4.8 Benelux Drugs for Central Nervous System Diseases Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Drugs for Central Nervous System Diseases Revenue, 2017-2028
  6.5.2 China Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.5.3 Japan Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.5.4 South Korea Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.5.5 Southeast Asia Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.5.6 India Drugs for Central Nervous System Diseases Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Drugs for Central Nervous System Diseases Revenue, 2017-2028
  6.6.2 Brazil Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.6.3 Argentina Drugs for Central Nervous System Diseases Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, 2017-2028
  6.7.2 Turkey Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.7.3 Israel Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.7.4 Saudi Arabia Drugs for Central Nervous System Diseases Market Size, 2017-2028
  6.7.5 UAE Drugs for Central Nervous System Diseases Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Alkermes
  7.1.1 Alkermes Corporate Summary
  7.1.2 Alkermes Business Overview
  7.1.3 Alkermes Drugs for Central Nervous System Diseases Major Product Offerings
  7.1.4 Alkermes Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.1.5 Alkermes Key News
7.2 Astrazeneca
  7.2.1 Astrazeneca Corporate Summary
  7.2.2 Astrazeneca Business Overview
  7.2.3 Astrazeneca Drugs for Central Nervous System Diseases Major Product Offerings
  7.2.4 Astrazeneca Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.2.5 Astrazeneca Key News
7.3 Biogen
  7.3.1 Biogen Corporate Summary
  7.3.2 Biogen Business Overview
  7.3.3 Biogen Drugs for Central Nervous System Diseases Major Product Offerings
  7.3.4 Biogen Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.3.5 Biogen Key News
7.4 Bristol Myers Squibb
  7.4.1 Bristol Myers Squibb Corporate Summary
  7.4.2 Bristol Myers Squibb Business Overview
  7.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Major Product Offerings
  7.4.4 Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.4.5 Bristol Myers Squibb Key News
7.5 Lilly
  7.5.1 Lilly Corporate Summary
  7.5.2 Lilly Business Overview
  7.5.3 Lilly Drugs for Central Nervous System Diseases Major Product Offerings
  7.5.4 Lilly Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.5.5 Lilly Key News
7.6 GSK
  7.6.1 GSK Corporate Summary
  7.6.2 GSK Business Overview
  7.6.3 GSK Drugs for Central Nervous System Diseases Major Product Offerings
  7.6.4 GSK Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.6.5 GSK Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Drugs for Central Nervous System Diseases Major Product Offerings
  7.7.4 Merck Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.7.5 Merck Key News
7.8 Sunovion Pharmaceuticals
  7.8.1 Sunovion Pharmaceuticals Corporate Summary
  7.8.2 Sunovion Pharmaceuticals Business Overview
  7.8.3 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Major Product Offerings
  7.8.4 Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.8.5 Sunovion Pharmaceuticals Key News
7.9 Pfizer
  7.9.1 Pfizer Corporate Summary
  7.9.2 Pfizer Business Overview
  7.9.3 Pfizer Drugs for Central Nervous System Diseases Major Product Offerings
  7.9.4 Pfizer Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.9.5 Pfizer Key News
7.10 Teva
  7.10.1 Teva Corporate Summary
  7.10.2 Teva Business Overview
  7.10.3 Teva Drugs for Central Nervous System Diseases Major Product Offerings
  7.10.4 Teva Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.10.5 Teva Key News
7.11 Norvatis
  7.11.1 Norvatis Corporate Summary
  7.11.2 Norvatis Business Overview
  7.11.3 Norvatis Drugs for Central Nervous System Diseases Major Product Offerings
  7.11.4 Norvatis Drugs for Central Nervous System Diseases Revenue in Global Market (2017-2022)
  7.11.5 Norvatis Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Drugs for Central Nervous System Diseases Market Opportunities & Trends in Global Market
Table 2. Drugs for Central Nervous System Diseases Market Drivers in Global Market
Table 3. Drugs for Central Nervous System Diseases Market Restraints in Global Market
Table 4. Key Players of Drugs for Central Nervous System Diseases in Global Market
Table 5. Top Drugs for Central Nervous System Diseases Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drugs for Central Nervous System Diseases Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drugs for Central Nervous System Diseases Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drugs for Central Nervous System Diseases Product Type
Table 9. List of Global Tier 1 Drugs for Central Nervous System Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Central Nervous System Diseases Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drugs for Central Nervous System Diseases Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drugs for Central Nervous System Diseases Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drugs for Central Nervous System Diseases Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2023-2028
Table 30. Alkermes Corporate Summary
Table 31. Alkermes Drugs for Central Nervous System Diseases Product Offerings
Table 32. Alkermes Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 33. Astrazeneca Corporate Summary
Table 34. Astrazeneca Drugs for Central Nervous System Diseases Product Offerings
Table 35. Astrazeneca Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 36. Biogen Corporate Summary
Table 37. Biogen Drugs for Central Nervous System Diseases Product Offerings
Table 38. Biogen Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 39. Bristol Myers Squibb Corporate Summary
Table 40. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product Offerings
Table 41. Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 42. Lilly Corporate Summary
Table 43. Lilly Drugs for Central Nervous System Diseases Product Offerings
Table 44. Lilly Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 45. GSK Corporate Summary
Table 46. GSK Drugs for Central Nervous System Diseases Product Offerings
Table 47. GSK Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Drugs for Central Nervous System Diseases Product Offerings
Table 50. Merck Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 51. Sunovion Pharmaceuticals Corporate Summary
Table 52. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Product Offerings
Table 53. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 54. Pfizer Corporate Summary
Table 55. Pfizer Drugs for Central Nervous System Diseases Product Offerings
Table 56. Pfizer Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 57. Teva Corporate Summary
Table 58. Teva Drugs for Central Nervous System Diseases Product Offerings
Table 59. Teva Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)
Table 60. Norvatis Corporate Summary
Table 61. Norvatis Drugs for Central Nervous System Diseases Product Offerings
Table 62. Norvatis Drugs for Central Nervous System Diseases Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Drugs for Central Nervous System Diseases Segment by Type in 2021
Figure 2. Drugs for Central Nervous System Diseases Segment by Application in 2021
Figure 3. Global Drugs for Central Nervous System Diseases Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drugs for Central Nervous System Diseases Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drugs for Central Nervous System Diseases Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2021
Figure 8. By Type - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 12. US Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 16. Germany Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 17. France Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 24. China Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 28. India Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 30. Brazil Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drugs for Central Nervous System Diseases Revenue Market Share, 2017-2028
Figure 33. Turkey Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drugs for Central Nervous System Diseases Revenue, (US$, Mn), 2017-2028
Figure 37. Alkermes Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Astrazeneca Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Biogen Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol Myers Squibb Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Lilly Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. GSK Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sunovion Pharmaceuticals Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Pfizer Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Teva Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Norvatis Drugs for Central Nervous System Diseases Revenue Year Over Year Growth (US$, Mn) & (2017-2022)